Heparin-induced thrombocytopenia

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 4, 2004, Pages 547-559

  Chong, Beng H ^a,c   Chong, James J H ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

Antibody; Heparin; Platelet; Thrombosis

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; ARGATROBAN; CLOPIDOGREL; DANAPAROID; DEXTRAN 70; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IMMUNOGLOBULIN G; LEPIRUDIN; PHENPROCOUMON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE FACTOR 4; TICLOPIDINE; WARFARIN; XIMELAGATRAN;

ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTERY THROMBOSIS; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LABORATORY DIAGNOSIS; LUNG EMBOLISM; PATHOPHYSIOLOGY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HUMANS; PLATELET FACTOR 4; RISK FACTORS; THROMBOCYTOPENIA;

EID: 4043094248     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.4.547     Document Type: Review

References (100)

1. Chong BH. Heparin-induced thrombocytopenia. Br. J. Haematol. 89, 31-439 (1995).
2. Warketin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb. Haemostas. 79, 1-7 (1998).
3. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complication with a heparin-dependent IgG antibody which induced platelet aggregation, release and thromboxane synthesis. Lancet II, 1246-1248 (1982).
4. Chong BH, Ismail F. The mechanism of heparin-induced platelet aggregation. Eur. J. Haematol. 43, 245-251 (1989).
5. Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low-molecular-weight heparin and heparinoid in intensive care patients and healthy controls. Eur. J. Haematol. 58, 270-285 (1997).
6. Mikhaildis DP, Barradas MA, Jeremy JY, Gracey L, Wakeling A, Dandona P. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur. J. Clin. Invest 15, 313-319 (1985).
7. Amiral J, Bridey F, Dreyfus M et al. Platelet Factor 4 complexed to heparin is die target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost. 68, 95-96 (1992).
8. Bell WR, Royall RM. Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N. Engl. J. Med. 303, 902-907 (1980).
9. Bailey RTJ, Ursick JA, Heim KL, Hilleman DE, Reich JW. Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin intestinal heparin. Drug Intel. Clin. Pharm. 20, 374-378 (1986).
10. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330-1335 (1995).
11. Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Ramirez-Lassepas M. Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther. Drug Monit. 5, 205-211 (1983).
12. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96, 1703-1708 (2000).
13. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, Inc., NY, USA, 107-148 (2004).
14. Chong B. Heparin-induced thrombocytopenia. In: Platelets. Michelson A (Ed.), Academic Press, NY, USA, 571-591 (2002).
15. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet Factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest. 93, 81-88 (1994).
16. Newman P, Chong BH. Heparin-induced thrombocytopenia: the major antigenic epitope is on the modified platelet Factor 4 and not on heparin. Br. J. Haematol. 107, 303-309 (1999).
17. Fabris FAS, Cella G, Jeska WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications - a review. Arch. Pathol. Lab. Med 124, 1657-1666 (2000).
18. Pouplard C, May MA, Iochmann S et al. Antibodies to platelet Factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99, 2530-3536 (1999).
19. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet Factor 4 antibodies after cat-diopulmonary bypass. Br. J. Haematol. 101, 653-655 (1998).
20. Chong BH, Ismail F, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br. J. Haematol. 73, 235-240 (1989).
21. Newman P, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purtied anti-PF4-heparin antibodies to platelets and the resulting activation. Blood 96, 182-187 (2000).
22. Kelton JG, Sheridan D, Santos A et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 72, 925-930 (1998).
23. Warkentin TE, Hayward CPM, Boshkov LK et al. Sera from patients with heparin-induced thrombocytopenia generated platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84, 3691-3699 (1994).
24. Chong BH, Grace CS, Rosenberg MC. Heparin-induced thrombocytopenia: effects of heparin platelet antibody on platelets. Brit. J. Haematol. 49, 531-540 (1981).
25. Pouplard C, Iochmann S, Renard B, Herault O, Gruel Y. Induction of monocyte tissue factor expression by antibodies to heparin-platelet Factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97, 3300-3302 (2001).
26. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin 8. Blood 98, 1252-1254 (2001).
27. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N. Engl. J. Med. 316, 581-589 (1987).
28. Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet Factor 4 by heparin. Thromb. Res. 27, 65-76 (1982).
29. Horne MKI, Chao ES. The effect of molecular weight on heparin binding to platelets. Br. J. Haematol. 74, 306-312 (1990).
30. Horne MKI, Hutchinson KJ. Simultaneous binding of heparin and platelet Factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocycopenia. Am. J. Hematol. 58, 24-30 (1998).
31. Visentin GP, Moghaddam M, Collins JI, McFarland JG, Aster RH. Antibodies associated with heparin-induced thrombocytopenia (HM report conformational changes in platelet Factor 4 (PF4) induced by linear polyanionic compounds. Blood 90(Suppl. 1), (1997) (Abstract 460a).
32. Amiral J, Marfaing-Koka. A, Wolf M et al. Presence of auto-antibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated-thrombocytopenia. Blood 88, 410-416 (1996).
33. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb. Haemost. 74, 886-892 (1995).
34. Ahmad S, Haas S, Hoppensteadt DA et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin Factor 4 antibodies. Thromb. Res. 108, 49-55 (2002).
35. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin platelet Factor 4 complexes. J. Lab. Clin. Med. 128, 376-383 (1996).
36. Amiral J, Wolf M, Fischer AM, Boyer-Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br. J. Haematol. 92, 954-959 (1996).
37. Nelson JC, Lerner RG, Goldstein R, Cagin NA. Heparin-induced thromboctyopenia. Arch. Intern. Med. 138, 548-552 (1978).
38. Warkentin TE. Clinical picture of HIT. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
39. Warkentin TE, Hong AP. Frequency of upper limb deep-venous thrombosis (UL-DVT) in relation to central venous catheter (CVC) use in patients with heparin-induced thrombocytopenia (HIT): evidence for interaction of systemic (HIT) and local (CVC) prothrombotic risk factors. Blood 92(Suppl. 1), 500a-510a (1998) (Abstract).
40. Natelson EA, Lynch EC, Alfrey CP Jr, Gross JB. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy, Ann. Intern. Med. 71, 1121-1125 (1969).
41. Klein HG, Bell WR. Disseminated intravascular coagulation during heparin therapy. Intern. Med. 80, 477-448 (1974).
42. Rhodes GR, Dixon RH, Silver D. Heparin-induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg. Gynecol. Obstet. 136, 409-416 (1973).
43. Warkentin TE, Soutar RL, Panju A, Ginsberg JS. Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin-induced thrombocytopenia. Blood 80 (Suppl. 1), (1992) (Abstract 160a).
44. Warkentin TE, Hirte HW, Anderson DR et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am. J. Med. Sci. 97, 489-491 (1994).
45. Greinacher A. Wakentin TE. Laboratory testing for heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
46. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb. Haemost. 69, 344-350 (1993).
47. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 67, 27-30 (1986).
48. Greinacher A, Michels J, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb. Haemost. 66, 734-736 (1991).
49. Stewart MW, Etches WS, Boshkov LK, Gordon PA. Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. Br. J. Haematol. 91, 173-177 (1995).
50. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br. J. Haematol. 98, 648-656 (1997).
51. Tomer A, Masalunga C, Abshire TC. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Am. J. Hematol. 61, 53-61 (1999).
52. Amiral J, Bridey F, Wolf M et al. Antibodies to macromolecular platelet Factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb. Haemost. 73, 21-28 (1995).
53. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross reactivity with low-molecular-weight heparin and heparinoid. Thromb. Haemost. 80, 292-297 (1998).
54. Wester J. New developments in thrombosis and hemostasis with a focus on critical care medicine. Nederlandse Vereniging voor Intensive Care 6, 20-23 (2002).
55. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr. Hematol. Rep. 2, 48-157 (2003).
56. Greinacher A, Janssens U, Berg G et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100, 587-593 (1999).
57. Greinacher A, Völpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study. Circulation 99, 73-80 (1999).
58. Chong BH. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
59. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 22, 85-91 (1992).
60. Chong BH. Prospective randomized open-label comparison of danaparoid wit dextran 70 in the treatment of heparin-induced thrombocytopenia. Thromb. Haemost. 86, 1170-1175 (2001).
61. Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
62. Amiral J, Lormeau JC, Marfaing-Koka A et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Goagul. Fibrinol. 8, 114-117 (1997).
63. Bartholomew J. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
64. Eriksson BI, Bergqvist D, Kalebo P et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet 360, 1441-1447 (2002).
65. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. 127, 804-812 (1997).
66. Greinacher A. Lepirudin for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
67. Greinacher A, Eichler P, Lubenow N, Kiefel V. Drug-induced and drug-dependent immune thrombocytopenias. Rev. Can. Exp. Hentatol. 5, 166-200 (2001).
68. Lubenow N, Eichler P, Greinacher A. Results of a large drug-monitoring program confirms the safety and efficacy of refludan (lepirudin) in patients with immunemediated heparin-induced thrombocytopenia (HIT). Blood 100(Suppl.), (2002) (Abstract 502a).
69. Greinacher A, Eichler P, Lubenow N. Anaphylactic reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT). Circulation 108, 2062-2065 (2003).
70. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org. 10172). Thromb. Haemost 70, 554-561 (1993).
71. Meuleman DG. Orgaran (Org. 10172): its pharmacological profile m experimental models. Haemostasis 22, 58-65 (1992).
72. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin. Hematol. 35(4 Suppl. 5), 3-8 (1998).
73. Warkentin TE. Danaparoid (orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation and evaluation of the clinical significance of in vitro cross reactivity of danaparoid for HIT-IgG. Blood 88, (1996) (Abstract 626a).
74. Tardy/Poncet B, Mahul P, Beraud AM, Favre JP, Tardy B, Guyotat D. Failure of orgaran therapy in a patient with a previous heparin-induced thrombocytopenia. Br. J. Haematol. 90, 69-70 (1995).
75. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838-1843 (2001).
76. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med. 163, 1849-1856(2003).
77. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. Clin. Pharmacol. Ther. 71, 433-439 (2002).
78. Chamberlin JR, Lewis B, Leya F et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can. J. Cardiol. 11, 511-514 (1995).
79. Francis JL, Drexler A, Gwyn G, Moroose R. Bivalirudin, a direct thrombin inhibitor, in the treatment of heparin-induced thrombocytopenia. Thromb. Haemost. (Suppl. 1) (2003) (Abstract 1909).
80. Boneu B, Necciari J, Cariou R. Pharmacokinetics and tolerance of the natural pentasaccharide (ORG31540/SR90107A) with high affinity to antithrombin III in man. Thromb. Haemost. 74, 1468-1473 (1995).
81. Buller HR, Davidson BL, Decousus H et al., and the Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349, 1695-1702 (2003).
82. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Erikson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokinet. 42, 381-392 (2003).
83. Olsson SB, and the Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 362, 1691-1698 (2003).
84. Cohen JI, Cooper MR, Greenberg GS. Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch. Intern. Med. 145, 1725-1726 (1985).
85. Sobel M, Adelman B, Szentpeterey S, Hofmann M, Posner MP, Jenvey W. Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism. J. Vasc. Surg. 8, 395-401 (1988).
86. Thorp D, Canty A, Whiting J et al. Plasma exchange and heparin-induced thrombocytopenia. Prog. Clin. Biol. Res. 337, 521-522 (1990).
87. Grau E, Linares M, Alaso, MA, Ruvira J, Sanchis J. Heparin-induced thrombocytopenia - response to intravenous immunoglobulin in vivo and in vitro. Am. J. Hematol. 39, 312 (1992).
88. Gruel Y, Lermusiaux P, Lang M et al. Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis. Ann. Vasc. Surg. 5, 552-555 (1991).
89. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 83, 1535-1541 (1994).
90. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. Sci. 101, 502-507 (1996).
91. Poetzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
92. Merry AF, Raudkivi PJ, Middleton NG et al. Bivalirudin versus heparin and protamine in off pump coronary artery bypass surgery. Ann. Thorac. Surg. 77(3), 925-931 (2004).
93. Kappa JR, Fisher CA, Todd B et al. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann. Thorac. Surg. 49, 714-722 (1990).
94. Laster J, Elfrin R, Silver D. Re-exposure to heparin of patients with heparin-associated antibodies. Vasc. Surg. 9, 677-681 (1989).
95. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F. ARG-216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc. Interv. 57, 177-184 (2002).
96. Jang I-K, Matthai WH, Kleiman NS. Combination of a direct thrombin inhibitor, argatroban, and glycoprotein IIb/IIIa. inhibitor is effective and safe in patients undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol. 91 (Suppl.) (2003) (Abstract 68a).
97. OASIS Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: a pilot study. Circulation 96, 769-777 (1997).
98. OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia wihtout ST elevation: a randominzed trial. Lancet 353, 429-438 (1999).
99. Mahaffey KW, Lewis BE, Wildermann NM et al., and the ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATRAT) study: main results. J. Invasive Cardiol. 15 (11), 611-616 (2003).
100. Fischer KG. Hemodialysis in heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).